Finch Therapeutics Group Inc Financials - Benzinga

Finch Therapeutics Group Inc

FNCHOTC

Trade with Public

Trade with Public

$1.80

At close: Jun 3, 5:00 PM EST

$12.03

10.23568.33%

After Hours: Mar 23, 9:26 AM EST

Overview News Earnings ForecastFinancialsSentiment Ownership Compare

Finch Therapeutics Group Inc Financials

Finch Therapeutics Group Inc (FNCH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Finch Therapeutics Gr Q4 EPS $(1.89) Up From $(16.80) YoY

Finch Therapeutics Gr (NASDAQ:FNCH) reported quarterly losses of $(1.89) per share. This is a 88.75 percent increase over losses of $(16.80) per share from the same period last year.

Happy Mohamed

PRO
Finch Therapeutics Gr Q3 EPS $(1.51) Up From $(25.38) YoY

Finch Therapeutics Gr (NASDAQ:FNCH) reported quarterly losses of $(1.51) per share. This is a 94.05 percent increase over losses of $(25.38) per share from the same period last year.

Benzinga Newsdesk

PRO
Finch Therapeutics' Cash Balance Of $41.7M Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditures Into 2025

Benzinga Newsdesk

PRO
Finch Therapeutics Gr Q1 EPS $(1.33) Down From $(0.52) YoY, Sales $107.00K Down From $354.00K YoY

Finch Therapeutics Gr (NASDAQ:FNCH) reported quarterly losses of $(1.33) per share. This is a 155.77 percent decrease over losses of $(0.52) per share from the same period last year. The company reported $107.00

Benzinga Newsdesk

Looking Into Finch Therapeutics Group's Return On Capital Employed

Benzinga Insights

Finch Therapeutics Group Q4 EPS $(0.56) Misses $(0.34) Estimate, Sales $8.00K

Michael Horton